(c) Population studies of insulin and cancer risk
| Study | Publish year country (study Yrs) |
Total (n) | Insulin analyzed | Increased risk? | |
|---|---|---|---|---|---|
| Yang et al. [85] retrospective cohort | 2004 United Kingdom (1987–2002) | 24,918 | Insulin analogues (types not specified) | Yes colorectal cancer |
|
| Donadon et al. [86] case control | 2008 Italy (1994–2006) | 955 | Insulin analogues (types not specified) | Yes hepatocellular cancer in insulin-treated males |
|
|
| |||||
| Hemkens et al. [87] retrospective cohort | 2009 German (1998–2005) | 127,031 | Aspart, glargine, human insulin, lispro | Yes may be dose dependent |
|
|
| |||||
| Jonasson et al. [88] retrospective cohort | 2009 Sweden (2005–2007) | 114,841 | Glargine | No | |
|
| |||||
| Colhoun et al. [89] retrospective cohort | 2009 Scotland (2002–2005) | 36,254 | Glargine | No | |
|
| |||||
| Currie et al. [90] retrospective cohort | 2009 United Kingdom (2000–2005) |
62,809 | Insulin analogues (types not specified) oral agents | No | |
|
| |||||
| Rosenstock et al. [91] randomized control | 2009 United States (5 years) | 1017 | NPH, glargine | No | |
|
| |||||
| Yang et al. [22] retrospective cohort | 2010 Hong Kong (1996–2005) | 4623 | Insulin analogues (types not specified) | No | |